Butalbital, APAP, Caf 50/325/40 Tablets, packaged in a) 12-count bottles, NDC: 63629-8392-09, bar...
FDA Drug Recall #D-0256-2022 — Class III — September 28, 2021
Recall Summary
| Recall Number | D-0256-2022 |
| Classification | Class III — Low risk |
| Date Initiated | September 28, 2021 |
| Status | Ongoing |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Bryant Ranch Prepack, Inc. dba BRP Pharmaceuticals |
| Location | Burbank, CA |
| Product Type | Drugs |
| Quantity | 119 Bottles |
Product Description
Butalbital, APAP, Caf 50/325/40 Tablets, packaged in a) 12-count bottles, NDC: 63629-8392-09, barcode 083929152151; b) 60-count bottles, NDC: 63629-8392-03, barcode 083923152614; c) 90-count bottles, NDC:63629-8392-04, barcode 083924152614, Lannett Company Inc; Rx only, Packaged by Bryant Ranch Prepack, Burbank, CA 91504.
Reason for Recall
Labeling: Not Elsewhere Classified: the controlled substance classification "CIII" is missing on the label
Distribution Pattern
Nationwide in the USA
Lot / Code Information
a) Lots: 152838, 152156, 152151, 151708, 151693, 151375, 151131, 151114, Exp: 7/31/2022, b) Lots: 152245, 151822, 151708, 151160, 151131, Exp: 7/31/2022, c) Lot #: 152614, Exp: 7/31/2022.
Other Recalls from Bryant Ranch Prepack, Inc. dba BRP Ph...
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0092-2022 | Class I | Methocarbamol 500mg Tablet, packaged in a) #30 ... | Oct 12, 2021 |
| D-0257-2022 | Class III | Butalbital, APAP, Caf 50/325/40 Tablet, package... | Sep 28, 2021 |
| D-0304-2021 | Class II | Spironolactone Tablets, USP, 50 mg, packaged in... | Jan 27, 2021 |
| D-0303-2021 | Class I | Spironolactone Tablets, USP, 25 mg, packaged in... | Jan 27, 2021 |
Frequently Asked Questions
Stop using the medication immediately and contact your pharmacist. A mislabeling recall can range from a minor technical error (wrong font size) to a serious mix-up where one drug is inside another drug's packaging. If you received a medication that looks or acts differently than expected, or if you experienced unexpected effects, tell your doctor immediately. The pharmacist can verify whether your specific lot is affected and provide a replacement. Report any adverse effects experienced to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.